Estradiol (E2) is the major molecular form of estrogens. Its biological effects are determined by estrogen receptors and intracellular E2 concentration in target cells. Regulation of intracellular E2 concentration involves the action of 17β-hydroxysteroid dehydrogenase (17HSD) type 2, the enzyme inactivating E2 to estrone. It has been demonstrated that 17HSD type 2 is expressed in normal endometrial epithelia and emdometrial carcinoma cells (RL 95-2). However, the regulatory mechanism of 17HSD type 2 expression in emdometrial cancer cells remains unknown. In the present study, the effects of transforming growth factor-β1 (TGF-β1) and epidermal growth factor (EGF) on 17HSD type 2 expression in RL 95-2 cells have been investigated using enzyme activity assay and Northern blot analysis. After stimulation with TGF-β1 or EGF, the in vivo oxidative 17HSD activity in RL 95-2 cells was significantly decreased. It appeared that the inhibitory effect of TGF-β1 and EGF on the enzyme activity of 17HSD type 2 is dose-and time-dependent. Northern blot analysis further revealed that treatment of cells for 48 h with 10 ng/mL TGF-1 β and 50 ng/mL EGF reduced the expression 17HSD type 2 mRNA to 30% and 20% of the control level, respectively. The data demonstrate that 17HSD type 2 expression in endometrial carcinoma cells is down-regulated by certain growth factors.
This is a preview of subscription content, log in to check access.
Labrie, F., Intracrinology, Mol. Cell Endocrinol., 1991, 78: C113.
Peltoketo, H., Luu-The, V., Simard, J. et al., 17 β-hydroxysteroid dehydrogenase/17-ketosteroid reductase family: nomenclature and main characteristics of the 17HSD/KSR enzymes, J. Mol. Endocrinol., 1999, 23: 1.
Miettinen, M. M., Mustonen, M. V. J., Poutanen, M. H. et al., Human 17 β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic celland tissue-specific expression, Biochem. J., 1996, 314: 839.
Mustonen, M. V. J., Isomaa, V. V., Tommi, V. et al., Human 17 β-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle, J. Clin. Endocrinol. Metab, 1998, 83: 1319.
Sutton, G., Hormonal aspects of endometrial cancer, Current Opin. Obstet Gynecol., 1990, 2: 69.
King, R. J. B., Biology of female sex hormone action in relation to contraceptive agents and neoplasia, Contraception, 1991, 43: 527.
Mäentausta, O., Svalander, P., Gemzell, D. K. et al., Immunohistochemical localization of 17 β-hydroxysteroid dehydrogenase (17HSD) in the human endometrium during the menstrual cycle, Lab Invest., 1991, 65: 582.
Casey, M. L., MacDonald, P. C., Andersson, S., 17 β-hydroxysteroid dehydrogenase type 2: Chromosomal assignment and progestin regulation of gene expression in human endometrium, J. Clin. Invest., 1994, 94: 2135.
Tseng, L., Gurpide, E., Changes in vitro metabolism of estradiol by human endometrium during the menstrual cycle, Am. J. Obstet. Gynecol., 1972, 114: 1002.
Way, D. L., Grosso, D. S., Davis, J. R. et al., Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture, In vitro, 1983, 19: 147.
Piao, Y. S., Peltoketo, H., Jouppila, A. et al., Retinoic acids increase 17 β-hydroxysteroid dehydrogenase type 1 expression in JEG-3 and T47D cells, but the stimulation is potentiated by epidermal growth factor, 12-O-tetradecanoulphorbol-13-acetate, and cyclic adenosine 3′, 5′-monophosphate only in JEG-3 cells, Endocrinology, 1997, 138: 898.
Leake, R., Carr, L., Rinaldi, F., Autocrine and paracrine effects in the endometrium, Ann. NYAcad. Sci., 1991, 622: 145.
Smith, S. K., Growth factors in the human endometrium, Hum. Reprod., 1994, 9: 936.
Jantus-Lewintre, E., Orava, M., Vihko, R., Regulation of 17β-hydroxysteroid dehydrogenase type 1 by epidermal growth factor and transforming growth factor alpha in choriocarcinoma cells, Endocrinology, 1994, 135: 2629.
Mäentausta, O., Boman, K., Isomma, V. et al., Immunohistochemical study of the human 17β-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma, Cancer, 1992, 70: 1551.
About this article
Cite this article
Li, X., Xiao, Z. & Piao, Y. Transforming growth factorβ1 and epidermal growth factor decrease the expression of 17β-hydroxysteroid dehydrogenase type 2 in endometrial carcinoma cells. Chin.Sci.Bull. 47, 44–47 (2002). https://doi.org/10.1360/02tb9008
- 17β-hydroxysteroid dehydrogenase
- growth factor